Pfizer Advances Battle Against COVID-19 on Multiple Fronts
• Anti-viral compounds show activity against SARS-CoV-2 in preclinical screening
• Pfizer and BioNTech enter into collaboration agreement to co-develop potential COVID-19 vaccine
• Company shares additional data and analysis of azithromycin
• Launch of two new studies to provide insights on the interaction between S. pneumoniae and SARS-CoV-2
• Pfizer explores studies of JAK inhibitor tofacitinib in patients with COVID-19-related pneumonia
NEW YORK, April 9, 2020 — Pfizer Inc. (NYSE: PFE) today announced important advances in the battle against the global COVID-19 pandemic.
As outlined in Pfizer’s five-point plan, the company has been collaborating across the healthcare innovation ecosystem ranging from large pharmaceutical companies to the smallest of biotech companies, from government agencies to academic institutions to address the COVID-19 global health care crisis. Researchers and scientists have been relentlessly working to develop an investigational antiviral compound to treat SARS-CoV-2, which causes the current pandemic of coronavirus infections (COVID-19), a vaccine to prevent infection as well as evaluating other therapies that have scientific potential to help infected patients fight the virus.
